[{"type": "title", "data": "Plan Name"}, {"type": "category", "data": "Medications"}, {"type": "note", "data": "For medical patients, refer to Venous Thromboembolism (VTE) Prophylaxis - Medicine (Module)", "value": ""}, {"type": "note", "data": "For obstetrical patients, refer to OB Postpartum VTE Thromboprophylaxis (Module)", "value": ""}, {"type": "note", "data": "Refer to VTE Risk Assessment and Thromboprophylaxis Recommendation", "value": ""}, {"type": "note", "data": "For patients receiving prophylactic subcutaneous enoxaparin up to 40 mg qdaily or dalteparin up to 5000 units qdaily or heparin up to 5000 units Q8H:  \n-Do not remove epidural/perineural catheter for at least 12 hours after the last dose of LMWH (enoxaparin or dalteparin) or at least 4 hours after the last dose of heparin \n-After catheter removal, do not administer LMWH (enoxaparin or dalteparin) for at least 4 hours or heparin for at least 1 hour", "value": ""}, {"type": "sentence", "data": "None"}, {"type": "note", "data": "VTE RISK IS LOW", "value": ""}, {"type": "order", "data": "Ambulate", "value": ""}, {"type": "sentence", "data": "No anticoagulant or no mechanical prophylaxis required"}, {"type": "note", "data": "VTE RISK IS MODERATE OR HIGH", "value": ""}, {"type": "note", "data": "Order pharmacologic prophylaxis except when: \n- Active bleeding of clinical significance requiring intervention  \n- High risk of serious bleeding or bleeding into a critical site (e.g. intracranial, epidural, pericardial, intraocular, retroperitoneal, intra-articular)   \n- Known major bleeding disorder or acquired coagulopathy (consider Hematology consult)   \n- Platelet count less than 50 x 10^9/L (consider Hematology consult)  \n- If history of Heparin-Induced Thrombocytopenia (HIT), DO NOT give LMWH or heparin. Consider fondaparinux (listed below) or consult Hematology / Internal Medicine for use of an alternative agent if eGFR less than 30mL/min\n- Patient already receiving therapeutic anticoagulation", "value": ""}, {"type": "order", "data": "VTE Prophylaxis Contraindication", "value": ""}, {"type": "sentence", "data": "Contraindication: Active Bleeding Requiring Intervention"}, {"type": "sentence", "data": "Contraindication: Risk of Serious Bleed in Critical Site"}, {"type": "sentence", "data": "Contraindication: Known Major Bleed Disorder/Coagulopathy"}, {"type": "sentence", "data": "Contraindication: Platelet Count Less Than 50 x 10^9/L"}, {"type": "sentence", "data": "Contraindication: Hx of Heparin-Induced Thrombocytopenia"}, {"type": "sentence", "data": "Contraindication: Receiving Therapeutic Anticoagulant"}, {"type": "note", "data": "For spinal surgery patients, recommended order first post-op dose 24 hours after admission to PACU", "value": ""}, {"type": "sentence", "data": "None"}, {"type": "order", "data": "Communication Order", "value": ""}, {"type": "sentence", "data": "For spinal surgery patients, give first post-op VTE prophylaxis  dose 24 hours after admission to PAC"}, {"type": "sentence", "data": "None"}, {"type": "note", "data": "Epidural / perineural is contraindicated if enoxaparin dose exceeds 40 mg daily or dalteparin dose exceeds 5000 units daily or heparin doses exceeds 5000 units q8h or fondaparinux any dose or rivaroxaban any dose", "value": ""}, {"type": "sentence", "data": "None"}, {"type": "note", "data": "enoxaparin for eGFR 30 mL/min or greater", "value": ""}, {"type": "order", "data": "enoxaparin", "value": ""}, {"type": "sentence", "data": "40 mg, subcutaneous, qAM, drug form: syringe-inj, start: T+1; 1000"}, {"type": "sentence", "data": "30 mg, subcutaneous, qAM, drug form: syringe-inj, start: T+1; 1000"}, {"type": "sentence", "data": "40 mg, subcutaneous, q12h, drug form: syringe-inj, start: T+1; 1000"}, {"type": "sentence", "data": "60 mg, subcutaneous, q12h, drug form: syringe-inj, start: T+1; 1000"}, {"type": "note", "data": "enoxaparin for eGFR 10 to 29 mL/min", "value": ""}, {"type": "order", "data": "enoxaparin", "value": ""}, {"type": "sentence", "data": "30 mg, subcutaneous, qAM, drug form: syringe-inj, start: T+1; 1000"}, {"type": "sentence", "data": "40 mg, subcutaneous, qAM, drug form: syringe-inj, start: T+1; 1000"}, {"type": "sentence", "data": "60 mg, subcutaneous, qAM, drug form: syringe-inj, start: T+1; 1000"}, {"type": "note", "data": "enoxaparin for patients with high risk poly-trauma / skeletal trauma. Contraindicated if epidural / perineural to be placed or in situ for neuraxial blockade", "value": ""}, {"type": "order", "data": "enoxaparin", "value": ""}, {"type": "sentence", "data": "30 mg, subcutaneous, q12h, drug form: syringe-inj, start: T+1; 1000"}, {"type": "sentence", "data": "30 mg, subcutaneous, q12h, drug form: syringe-inj, start: T+1; 2200"}, {"type": "note", "data": "heparin for eGFR less than 10 mL/min or on dialysis", "value": ""}, {"type": "order", "data": "heparin", "value": ""}, {"type": "sentence", "data": "2,500 unit, subcutaneous, q12h, drug form: inj, start: T+1;1000"}, {"type": "sentence", "data": "2,500 unit, subcutaneous, q12h, drug form: inj, start: T+1;2200"}, {"type": "sentence", "data": "5,000 unit, subcutaneous, q12h, drug form: inj, start: T+1;1000"}, {"type": "sentence", "data": "5,000 unit, subcutaneous, q12h, drug form: inj, start: T+1;2200"}, {"type": "sentence", "data": "5,000 unit, subcutaneous, q8h, drug form: inj, start:T+1;0600"}, {"type": "sentence", "data": "5,000 unit, subcutaneous, q8h, drug form: inj, start:T+1;2200"}, {"type": "note", "data": "heparin for patients with epidural / perineural catheter and weight 101 kg or greater and eGFR 30 mL/min or greater; or weight 141 kg or greater and eGFR less than 30 mL/min ", "value": ""}, {"type": "sentence", "data": "None"}, {"type": "sentence", "data": "5,000 unit, subcutaneous, q8h, drug form: inj"}, {"type": "note", "data": "High risk patients who need prophylaxis on post operative DAY ZERO. This is a one time dose", "value": ""}, {"type": "order", "data": "heparin ", "value": ""}, {"type": "sentence", "data": "5,000 unit, subcutaneous, once, drug form: inj. start: T; 2200"}, {"type": "sentence", "data": "5,000 unit, subcutaneous, once, drug form: inj. start: T; 1800"}, {"type": "sentence", "data": "5,000 unit, subcutaneous, once, drug form: inj. start: T; 1900"}, {"type": "sentence", "data": "5,000 unit, subcutaneous, once, drug form: inj. start: T; 2000"}, {"type": "sentence", "data": "5,000 unit, subcutaneous, once, drug form: inj. start: T; 2100"}, {"type": "sentence", "data": "5,000 unit, subcutaneous, once, drug form: inj. start: T; 2300"}, {"type": "note", "data": "Non-Traumatic Spinal Cord Injury (SCI) OR Spinal Column Injury without SCI", "value": ""}, {"type": "sentence", "data": "None"}, {"type": "order", "data": "dalteparin", "value": ""}, {"type": "sentence", "data": "2,500 unit, subcutaneous, qAM, drug form: syringe-inj, start: T+1;1000"}, {"type": "sentence", "data": "2,500 unit, subcutaneous, qPM, drug form: syringe-inj, start: T+1;1700"}, {"type": "sentence", "data": "5,000 unit, subcutaneous, qAM, drug form: syringe-inj, start: T+1;1000"}, {"type": "sentence", "data": "5,000 unit, subcutaneous, qPM, drug form: syringe-inj, start: T+1;1700"}, {"type": "sentence", "data": "5,000 unit, subcutaneous, q12h, drug form: syringe-inj, start: T+1;1000"}, {"type": "sentence", "data": "5,000 unit, subcutaneous, q12h, drug form: syringe-inj, start: T+1;2200"}, {"type": "note", "data": "fondaparinux for patients with heparin-induced thrombocytopenia and eGFR 30 mL/min or greater. Consider consulting Hematology / Internal Medicine regarding the use of alternative agents if eGFR less than 30 mL/min. Contraindicated if epidural / perineural to be placed or in situ", "value": ""}, {"type": "order", "data": "fondaparinux", "value": ""}, {"type": "sentence", "data": "2.5 mg, subcutaneous, qAM, drug form: syringe-inj, start: T+1; 1000"}, {"type": "note", "data": "rivaroxaban restricted for post-hip or knee arthroplasty.  Contraindicated if epidural / perineural to be placed or in situ or e-GFR is less than 30 mL/min. Please specify number of days within medication order", "value": ""}, {"type": "note", "data": "Total Knee Replacement", "value": ""}, {"type": "order", "data": "rivaroxaban", "value": ""}, {"type": "sentence", "data": "10 mg, PO, qAM, order duration: 14 day, drug form: tab, start: T+1; 1000"}, {"type": "note", "data": "Total Hip  Replacement", "value": ""}, {"type": "order", "data": "rivaroxaban", "value": ""}, {"type": "sentence", "data": "10 mg, PO, qAM, order duration: 35 day, drug form: tab, start: T+1; 1000"}, {"type": "note", "data": "ASA EC for post hip or knee surgery if on mechanical prophylaxis only", "value": ""}, {"type": "order", "data": "ASA EC", "value": ""}, {"type": "sentence", "data": "162 mg, PO, qdaily with food, drug form: tab-EC"}, {"type": "note", "data": "VTE RISK IS MODERATE OR HIGH WITH CONTRAINDICATION TO ANTICOAGULANTS", "value": ""}, {"type": "note", "data": "Mechanical prophylaxis contraindicated in: \n- Peripheral vascular disease with absent pedal pulses  \n- Severe peripheral neuropathy  \n- Skin breakdown, ulcers, gangrene, cellulitis, or dermatitis  \n- Skin grafting within last 3 months \n- Allergy to stocking or compression cuff materials \n- Unable to size or apply properly due to deformity, recent surgery or trauma  \n- Acute stroke with immobility (unable to walk independently to the toilet) should not use graduated compression stockings or calf-length / below the knee Sequential Compression Devices. Thigh-length / full length Sequential Compression Device should be utilized", "value": ""}, {"type": "sentence", "data": "None"}, {"type": "order", "data": "Apply Below the Knee Graduated Compression Stocking", "value": ""}, {"type": "sentence", "data": "Apply to lower limb(s) continuously until anticoagulant prophylaxis starts or discharge. Interrupt for skin care, assessments, toileting, and ambulation only"}, {"type": "order", "data": "Apply Full Leg Sequential Compression Devices", "value": ""}, {"type": "sentence", "data": "Apply to lower limb(s) continuously until anticoagulant prophylaxis starts or discharge. Interrupt for skin care, assessments, toileting, and ambulation only"}, {"type": "order", "data": "Apply Below the Knee Sequential Compression Devices", "value": ""}, {"type": "sentence", "data": "Apply to lower limb(s) continuously until anticoagulant prophylaxis starts or discharge. Interrupt for skin care, assessments, toileting, and ambulation only"}, {"type": "order", "data": "Communication Order", "value": ""}, {"type": "sentence", "data": "No mechanical prophylaxis because of contraindication(s)"}]
